natgillin/translations-raw huggingface dataset:
From entry into the randomized studies,5.3 % of the subjects exposed to brivaracetam for 6 months (n=1,500) were seizure free compared to 4.6 % and 3.7 % for subjects exposed for 12 months (n=1,188) and 24 months (n=847), respectively. 
Od trenutka uključivanja u randomizirana ispitivanja, 5,3% ispitanika izloženih brivaracetamu tijekom 6 mjeseci (n=1500) bilo je bez napadaja, a isto je zabilježeno i u 4,6% ispitanika izloženih lijeku tijekom 12 mjeseci (n=1188) te 3,7% onih koji su mu bili izloženi tijekom 24 mjeseca (n=847).
No dose adjustment is needed in patients with impaired renal function (see section 5.2). 
Nije potrebno prilagođavati dozu u bolesnika s oštećenjem bubrežne funkcije (vidjeti dio 5.2).
50 mg/day 100 mg/day 200 mg/day 
50 mg/dan 100 mg/dan 200 mg/dan
The solution for injection/infusion contains 0.83 mmol (or 19.14 mg) sodium per vial. 
Otopina za injekciju/infuziju sadrži 0,83 mmol (ili 19,14 mg) natrija po bočici.
Oral dosing syringe (10 ml graduated every 0.25 ml) with an adaptor, recommended for use by patients weighing more than 20 kg or needing a dose between 50 mg and 100 mg (5 ml to 10 ml) brivaracetam per administration. 
Štrcaljka za oralno doziranje (10 ml graduirano na svakih 0,25 ml) s nastavkom, preporučena je za primjenu u bolesnika s tjelesnom težinom većom od 20 kg ili kojima je potrebna doza između 50 mg i 100 mg (5 ml do 10 ml) brivaracetama po primjeni.
- Periodic safety update reports 
• Periodička izvješća o neškodljivosti
- Pull the plunger down to fill the oral syringe with a small amount of solution (figure 6). 
- Povlačite klip prema dolje kako biste uvukli malu količinu otopine u štrcaljku za usta (slika 6).
Briviact may be diluted with the following solutions: sodium chloride 9 mg/ml (0.9 %), glucose 50 mg/ml (5 %) solution for injection or lactated Ringer's solution. 
Briviact se može razrijediti sljedećim otopinama: otopinom natrijeva klorida za injekcije od 9 mg/ml (0,9%), otopinom glukoze za injekcije od 50 mg/ml (5%) ili otopinom Ringerova laktata.
The other ingredients are: sodium citrate, citric acid anhydrous, methyl parahydroxybenzoate (E218), carmellose sodium, sucralose, sorbitol liquid, glycerol (E422), raspberry flavour, water, purified. 
Drugi sastojci su: natrijev citrat, bezvodna citratna kiselina, metilparahidroksibenzoat (E218), karmelozanatrij, sukraloza, tekući sorbitol, glicerol (E422), aroma maline, pročišćena voda.
From the pooled open-label safety and PK studies in adjunctive therapy, 149 children with POS have received brivaracetam, of whom 116 have been treated for ≥6 months, 107 for ≥12 months, 58 for ≥24 months, and 28 for ≥36 months. 
Iz združenih otvorenih ispitivanja sigurnosti i FK s adjunktivnom terapijom, 149 djece s parcijalnim nastupom napadaja (POS) primalo je brivaracetam, od kojih je 116 liječeno ≥6 mjeseci, 107 ≥12 mjeseci, 58 ≥24 mjeseca, a 28 ≥36 mjeseci.
The efficacy outcomes are summarized in Table 2. 
Ishodi djelotvornosti sažeto su prikazani u Tablici
In vitro, brivaracetam did ot induce CYP1A2. 
In vitro, brivaracetam nije inducirao CYP1A2.
n= 96 n= 101 
n=101
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine. 
Ako Vam je liječnik rekao da ne podnosite neke šećere, savjetujte se sa svojim liječnikom prije uzimanja ovog lijeka.
- Turn the bottle upside down (figure 5). 
- Preokrenite bocu (slika 5).
In the table below, adverse reactions, which were identified based on review of the three placebocontrolled, fixed-dose studies safety database in subjects ≥ 16 years of age, are listed by System Organ Class and frequency. 
Nuspojave identificirane na temelju pregleda tri placebom kontrolirana klinička ispitivanja s fiksnom dozom u ispitanika ≥ 16 godina starosti, navedene su u tablici u nastavku prema klasifikaciji organskih sustava i učestalosti.
The minimum extractible volume is 0.25 ml which is 2.5 mg of brivaracetam. 
Najmanji volumen koji se može ekstrahirati je 0,25 ml, što odgovara 2,5 mg brivaracetama.
CYP2B6 induction has not been investigated in vivo and brivaracetam may decrease plasma concentrations of medicinal products metabolised by CYP2B6 (e.g. efavirenz). 
Indukcija enzima CYP2B6 nije se ispitivala in vivo i brivaracetam može smanjiti plazmatske koncentracije lijekova metaboliziranih enzimom CYP2B6 (npr. efavirenza).
Oral dosing syringe (5 ml graduated every 0.1 ml) with an adaptor, recommended for use by patients weighing less than 20 kg or needing a maximum of 50 mg (5 ml) brivaracetam per administration. 
Štrcaljka za oralno doziranje (5 ml graduirano na svakih 0,1 ml) s nastavkom, preporučena je za primjenu u bolesnika s tjelesnom težinom manjom od 20 kg ili kojima je potrebno najviše 50 mg (5 ml) brivaracetama po primjeni.
The main disposition pathway of brivaracetam is by CYP-independent hydrolysis. 
Glavni put biotransformacije brivaracetama je hidroliza neovisna o CYP enzimima.
In particular, tell your doctor if you are taking any of the following medicines - this is because your doctor may need to adjust your Briviact dose: - Rifampicin - a medicine used to treat bacterial infections. 
Posebno, obavijestite svog liječnika ako uzimate bilo koji od sljedećih lijekova - to je stoga što će Vaš liječnik možda trebati prilagoditi Vašu dozu Briviacta: rifampicin, lijek koji se koristi za liječenje bakterijskih infekcija. gospinu travu, (također poznatu kao Hypericum perforatum) biljni lijek koji se koristi za liječenje depresije i tjeskobe, kao i drugih stanja.
Children (≥4 years) and adolescents ≥50 kg Administered in 2 equally divided doses 
Djeca (≥4 godine) i adolescenti ≥50 kg Primjena u 2 jednake doze
Based on individual patient response, the dose may be adjusted in the effective dose range of 1 mg/kg/day and 4 mg/kg/day. 
Na osnovi pojedinačnog odgovora bolesnika, doza se može prilagođavati u djelotvornom rasponu doze od 1 mg/kg/dan i 4 mg/kg/dan.
Table 1: Pharmacokinetic interactions between brivaracetam and other AEDs AED coadministered Influence of AED on brivaracetam plasma concentration 
Tablica 1: Farmakokinetičke interakcije između brivaracetama i drugih antiepileptika Istodobno primijenjen antiepileptik
The primary endpoints in the phase 3 studies were the percent reduction in POS frequency over placebo and the 50 % responder rate based on 50 % reduction in POS frequency from baseline. 
Primarne mjere ishoda u ispitivanjima faze 3 bile su postotno smanjenje učestalosti parcijalnih napadaja u odnosu na placebo i stopa bolesnika s odgovorom od 50%, određenim na temelju smanjenja učestalosti parcijalnih napadaja za 50% u odnosu na početak ispitivanja.
Brivaracetam solution for injection/infusion is an alternative for patients when oral administration is temporarily not feasible. 
Brivaracetam otopina za injekciju/infuziju predstavlja zamjensku opciju za bolesnike u kojih peroralna primjena privremeno nije moguća.
INTERMEDIATE CARTON WITHIN MULTIPACK (3 PACKS OF 56 FILM-COATED TABLETS) (WITHOUT BLUEBOX) 
UNUTARNJE PAKIRANJE KAO DIO VIŠESTRUKOG PAKIRANJA (3 PAKIRANJA OD 56 FILMOM OBLOŽENIH TABLETA) (BEZ PLAVOG OKVIRA)
No adverse liver changes were seen in rats and monkeys following chronic administration of brivaracetam at 5- and 42fold the clinical AUC exposure. 
Štetne promjene na jetri nisu primijećene u štakora ni majmuna nakon kronične primjene brivaracetama u dozama kojima se postiže izloženost 5 odnosno 42 puta veća od one koja se postiže uz klinički AUC.
Contains sodium citrate, carmellose sodium, methyl parahydroxybenzoate (E218), sorbitol liquid and glycerol (E422). 
Sadrži natrijev citrat, karmelozunatrij, metilparahidroksibenzoat (E218), tekući sorbitol i glicerol (E422).
The minimum extractible volume is 1 ml which is 10 mg of brivaracetam. 
Najmanji volumen koji se može ekstrahirati je 1 ml, što odgovara 10 mg brivaracetama.
Croscarmellose sodium, lactose monohydrate, betadex, lactose anhydrous, magnesium stearate 
Jezgra umrežena karmelozanatrij, laktoza hidrat, betadeks, bezvodna laktoza, magnezijev stearat
PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND IMMEDIATE PACKAGING 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM I UNUTARNJEM PAKIRANJU
Binding to SV2A is believed to be the primary mechanism for brivaracetam anticonvulsant activity. 
Vjeruje se da je vezivanje za SV2A primarni mehanizam kojim brivaracetam ostvaruje svoje antikonvulzivno djelovanje.
The active substance is brivaracetam. 
Djelatna tvar je brivaracetam.
Suicidal ideation has been reported in 0.3 % (3/1099) brivaracetam patients and 0.7 % (3/459) placebo patients. 
Suicidalne ideje prijavljene su u 0,3% (3/1099) bolesnika liječenih brivaracetamom i 0,7% (3/459) bolesnika koji su primali placebo.
In all controlled and uncontrolled trials in patients with epilepsy, 2,388 subjects have received brivaracetam, of whom 1,740 have been treated for ≥ 6 months,1,363 for ≥ 12 months, 923 for ≥ 24 months and 569 for ≥ 60 months (5 years). 
U svim kontroliranim i nekontroliranim ispitivanjima provedenima u bolesnika s epilepsijom, brivaracetam je primalo 2388 ispitanika; 1740 njih liječeno je ≥ 6 mjeseci, 1363 ≥ 12 mjeseci, 923 ≥ 24 mjeseca, a njih 569 ≥ 60 mjeseci (5 godina).
As from the 1 ml graduation mark, each graduation corresponds to 0.25 ml which is 2.5 mg of brivaracetam. 
Od oznake gradusa od 1 ml, svaki gradus odgovara 0,25 ml, što je 2,5 mg brivaracetama.
Each millilitre (ml) contains 10 milligrams (mg) brivaracetam. 
Jedan mililitar (ml) sadrži 10 miligrama (mg) brivaracetama.
n = 252 n = 249 
n=252
Brivaracetam film-coated tablets contain lactose. 
Filmom obložene tablete brivaracetama sadrže laktozu.
Neutropenia has been reported in 0.5 % (6/1099) brivaracetam patients and 0 % (0/459) placebo patients. 
Neutropenija je prijavljena u 0,5% (6/1099) bolesnika liječenih brivaracetamom i 0% (0/459) bolesnika koji su primali placebo.
Instructions for use are provided in the package leaflet. 
Upute za primjenu navedene su u uputi za lijek.
1 - 4 mg/kg/day 
1 - 4 mg/kg/dan
The efficacy of brivaracetam in monotherapy has not been established. 
Nije utvrđena djelotvornost brivaracetama u monoterapiji.
Oral solution Slightly viscous, clear colourless to yellowish liquid. 
Oralna otopina Blago viskozna, bistra, bezbojna do žućkasta tekućina.
An additional adverse reaction reported in children was psychomotor hyperactivity 
Dodatna nuspojava prijavljena u djece bila je psihomotorička hiperaktivnost (4,7%).
Talk to your doctor or pharmacist before taking Briviact if: - You have thoughts of harming or killing yourself. 
Upozorenja i mjere opreza Obratite se svom liječniku ili ljekarniku prije nego uzmete Briviact: - ako razmišljate o samoozljeđivanju ili samoubojstvu.
Based on individual patient response, the dose may be adjusted in the effective dose range of 50 mg/day and 200 mg/day. 
Na osnovi pojedinačnog odgovora bolesnika, doza se može prilagođavati u djelotvornom rasponu doze od 50 mg/dan i 200 mg/dan.
Briviact is administered as an injection or infusion into a vein by a doctor or a nurse. 
Briviact će Vam dati liječnik ili medicinska sestra u obliku injekcije ili infuzije u venu.
Check with your doctor which one you should use. 
Provjerite sa svojim liječnikom koristite li odgovarajuću štrcaljku.
Diluents - Sodium chloride 9 mg/ml (0.9 %) solution for injection - Glucose 50 mg/ml (5 %) solution for injection - Lactated Ringer's solution for injection. 
Sredstva za razrjeđivanje - otopina natrijeva klorida za injekciju od 9 mg/ml (0,9%) - otopina glukoze za injekciju od 50 mg/ml (5%) - otopina Ringerova laktata za injekciju
Briviact contains sodium 
Briviact sadrži natrij
Common: may affect up to 1 in 10 people - flu - feeling very tired (fatigue) - convulsion, a feeling of ‘spinning' (vertigo) - feeling and being sick, constipation - depression, anxiety, not being able to sleep (insomnia), irritability - infections of the nose and throat (such as the ‘common cold'), cough - decreased appetite 
Česte: mogu se javiti u do 1 na 10 osoba - gripa - izrazit umor - konvulzija, vrtoglavica (osjećaj da se sve oko Vas vrti) - mučnina, povraćanje, zatvor - depresija, tjeskoba, nesanica, razdražljivost - infekcije nosa i grla (poput prehlade), kašalj - smanjen apetit
Brivaracetam oral solution contains sodium. 
Brivaracetam oralna otopina sadrži natrij.
How to take Briviact 
Kako uzimati Briviact
The discontinuation rate due to adverse reactions was 3.5 %, 3.4 % and 4.0 % for patients randomized to brivaracetam at respectively the dose of 50 mg/day, 100 mg/day and 200 mg/day and 1.7 % for patients randomized to placebo. 
Stopa prekida liječenja zbog nuspojava iznosila je 3,5%, 3,4% i 4,0% u bolesnika randomiziranih za primanje brivaracetama u dozi od 50 mg/dan, 100 mg/dan odnosno 200 mg/dan te 1,7% u bolesnika randomiziranih za primanje placeba.
The percentages of patients with at least a 50 % reduction in seizure frequency were 20.3 %, 34.2 %, 39.5 %, and 37.8 % for placebo, 50 mg/day, 100 mg/day, and 200 mg/day, respectively. 
Postotak bolesnika u kojih se učestalost parcijalnih napadaja smanjila za najmanje 50% iznosio je 20,3% uz placebo, 34,2% uz dozu od 50 mg/dan, 39,5% uz dozu od 100 mg/dan i 37,8% uz dozu od 200 mg/dan.
Briviact 10 mg/ml solution for injection/infusion 5 ml vial is packed in a carton box of 10 vials. 
Bočica s 5 ml lijeka Briviact 10 mg/ml otopina za injekciju/infuziju pakirana je u kutiju koja sadrži 10 bočica.
Briviact contains the active substance brivaracetam. 
Briviact sadrži djelatnu tvar brivaracetam.
Talk to your doctor or pharmacist before using Briviact if: - You have thoughts of harming or killing yourself. 
Upozorenja i mjere opreza Obratite se svom liječniku ili ljekarniku prije nego primjenite Briviact: - ako razmišljate o samoozljeđivanju ili samoubojstvu.
Contains croscarmellose sodium, lactose monohydrate and lactose anhydrous. 
Sadrži umreženu karmelozunatrij, laktozu hidrat i bezvodnu laktozu.
The 300 ml glass bottle of Briviact is packed in a cardboard box containing a 10 ml oral syringe and a 5 ml oral syringe and an adaptor for the syringe. 
Staklena boca lijeka Briviact od 300 ml pakirana je u kutiju koja sadrži štrcaljku za usta od 10 ml i od 5 ml i nastavak za štrcaljku.
Suicidal ideation, psychotic disorder, aggression, agitation Nervous system disorders Very common Dizziness, somnolence Common 
Psihijatrijski poremećaji često depresija, anksioznost, nesanica, razdražljivost manje često suicidalne ideje, psihotični poremećaj, agresivnost, agitacija Poremećaji živčanog sustava vrlo često omaglica, somnolencija često konvulzija, vrtoglavica
n = randomised patients who received at least 1 dose of study medication ~ Dose not studied Statistically significant Approximately 20 % of the patients were on concomitant levetiracetam The primary outcome for N01252 did not achieve statistical significance based on the sequential testing procedure. 
= randomizirani bolesnici koji su primili najmanje 1 dozu ispitivanog lijeka ~ Doza na kojoj nije provedeno ispitivanje Statistički značajno Približno 20% bolesnika istodobno se liječilo levetiracetamom
The pharmacokinetics of brivaracetam was not significantly affected by race (Caucasian, , Asian) in a population pharmacokinetic modeling from epilepsy patients. 
Populacijsko farmakokinetičko modeliranje provedeno u bolesnika s epilepsijom pokazalo je da rasa (bijela, azijska) nije značajno utjecala na farmakokinetiku brivaracetama.
One full 10 ml oral dosing syringe corresponds to 100 mg of brivaracetam. 
Jedna puna štrcaljka za oralno doziranje od 10 ml odgovara 100 mg brivaracetama.
It is unknown whether brivaracetam is excreted in human breast milk. 
Nije poznato izlučuje li se brivaracetam u majčino mlijeko u ljudi.
Driving and using machines - You may feel sleepy, dizzy or tired while taking Briviact. 
Upravljanje vozilima i strojevima - Tijekom liječenja lijekom Briviact možete osjećati pospanost, omaglicu ili umor.
50 mg/5 ml 10 vials solution for injection/infusion 
50 mg/5 ml 10 bočica s otopinom za injekciju/infuziju
UNIQUE IDENTIFIER - 2D BARCODE <2D barcode carrying the unique identifier included.> 
JEDINSTVENI IDENTIFIKATOR - 2D BARKOD <Sadrži 2D barkod s jedinstvenim identifikatorom.>
People with liver problems If you have problems with your liver: - As an adult, adolescent or child weighing 50 kg or more, the maximum dose you will take is 75 mg twice a day. 
Ako imate jetrenih tegoba: - kao odrasla osoba, adolescent ili dijete s tjelesnom težinom od 50 kg ili više, najveća doza koju ćete uzimati bit će 75 mg dvaput dnevno.
Briviact 10 mg film-coated tablets Briviact 25 mg film-coated tablets Briviact 50 mg film-coated tablets Briviact 75 mg film-coated tablets Briviact 100 mg film-coated tablets 
Briviact 10 mg filmom obložene tablete Briviact 25 mg filmom obložene tablete Briviact 50 mg filmom obložene tablete Briviact 75 mg filmom obložene tablete Briviact 100 mg filmom obložene tablete
What Briviact looks like and contents of the pack Briviact 10 mg/ml oral solution is slightly viscous, clear, colourless to yellowish liquid. 
Briviact 10 mg/ml oralna otopina je blago viskozna, bistra, bezbojna do žućkasta tekućina.
One full 5 ml oral dosing syringe corresponds to 50 mg of brivaracetam. 
Jedna puna štrcaljka od 5 ml za oralno doziranje odgovara 50 mg brivaracetama.
Adverse reactions with intravenous administration generally appeared to be similar to those observed with oral administration. 
Nuspojave koje su se javljale kod intravenske primjene načelno su bile slične onima primijećenima kod peroralne primjene.
Briviact 10 mg film-coated tablets Briviact 25 mg film-coated tablets Briviact 50 mg film-coated tablets Briviact 75 mg film-coated tablets Briviact 100 mg film-coated tablets brivaracetam 
Briviact 10 mg filmom obložene tablete Briviact 25 mg filmom obložene tablete Briviact 50 mg filmom obložene tablete Briviact 75 mg filmom obložene tablete Briviact 100 mg filmom obložene tablete brivaracetam
Each ml of solution for injection/infusion contains 10 mg brivaracetam. 
Jedan ml oralne otopine za injekciju/infuziju sadrži 10 mg brivaracetama.
Blood and lymphatic system disorders 
Poremećaji krvi i limfnog sustava manje često Neutropenija
Children and adolescents weighing less than 50 kg - The recommended dose is from 0.5 mg to 2 mg for each kg of bodyweight, taken twice a day. 
Djeca i adolescenti s tjelesnom težinom manjom od 50 kg - Preporučena doza iznosi od 0,5 mg do 2 mg po kilogramu tjelesne težine, uzimana dvaput dnevno.
What Briviact looks like and contents of the pack Briviact 10 mg/ml solution for injection/infusion is a clear, colourless, sterile solution. 
Briviact 10 mg/ml otopina za injekciju/infuziju je bistra, bezbojna, sterilna otopina.
Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. 
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji i blisteru iza oznake „Rok valjanosti“ / „EXP“.
Sodium acetate (trihydrate) Acetic acid, glacial (for pH-adjustment) Sodium chloride 
6.1 Popis pomoćnih tvari natrijev acetat (trihidrat) acetatna kiselina, ledena (za podešavanje pH) natrijev klorid voda za injekcije
A decision should be made whether to discontinue breastfeeding or to discontinue brivaracetam, taking into account the benefit of the medicinal product to the mother. 
Uzimajući u obzir korist lijeka za majku, treba donijeti odluku o tome hoće li se prekinuti dojenje ili obustaviti liječenje brivaracetamom.
Briviact 10 mg/ml solution for injection/infusion 
Briviact 10 mg/ml otopina za injekciju/infuziju
Children (from 4 years of age) and adolescents weighing 50 kg or more The recommended starting dose is 50mg/day. 
Djeca (od navršene 4 godine) i adolescenti s tjelesnom težinom od 50 kg ili više Preporučena početna doza je 50 mg/dan.
Do not use this medicine after the expiry date which is stated on the cardboard box and bottle after EXP. 
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji i bočici iza oznake „Rok valjanosti“ / „EXP“.
- As a child or adolescent weighing less than 50 kg, the maximum dose you will take is 1.5 mg for each kg of bodyweight twice a day. 
- kao dijete ili adolescent s tjelesnom težinom manjom od 50 kg, najveća doza koju ćete uzimati je 1,5 mg za svaki kg tjelesne težine, uzimana dvaput dnevno.
In children and adolescents weighing less than 50 kg, a 1 mg/kg/day starting dose is recommended. 
U djece i adolescenata koji teže manje od 50 kg, preporučuje se početna doza od 1 mg/kg/dan.
Based on individual patient response and tolerability, the dose may be adjusted in the dose range of 50 mg/day to 200 mg/day. 
Ovisno o odgovoru i podnošljivosti lijeka u pojedinog bolesnika, doza se može prilagođavati unutar raspona od 50 mg/dan do 200 mg/dan.
As a child or adolescent weighing less than 50 kg, the maximum dose you will take is 1.5 mg for each kg of bodyweight twice a day. 
Kao dijete ili adolescent s tjelesnom težinom manjom od 50 kg, najveća doza koju ćete uzimati je 1,5 mg za svaki kg tjelesne težine, uzimana dvaput dnevno.
What Briviact is 
Što je Briviact
10 mg/ml solution for injection/infusion is packed in 6 ml nominal capacity glass vials (type I) with siliconized bromobutyl rubber stoppers and sealed with an aluminium/polypropylene tear off cap. Each single use vial contains an extractable volume of not less than 5.0 ml of solution for injection/infusion. 
Otopina za injekciju/infuziju od 10 mg/ml pakirana je u staklene bočice (staklo tipa I) deklariranog volumena 6 ml s čepovima od silikonizirane brombutilne gume i aluminijskim/polipropilenskim zaštitnim zatvaračem koji se otkida.
Volumes of oral solution to be taken per administration 
Volumeni oralne otopine koji se uzimaju po primjeni
You will take Briviact together with other medicines for epilepsy. 
Briviact ćete uzimati zajedno s drugim lijekovima za epilepsiju.
Briviact 10 mg film-coated tablets Each 10 mg film-coated tablet contains 88 mg lactose. 
Briviact 10 mg filmom obložene tablete Jedna filmom obložena tableta od 10 mg sadrži 88 mg laktoze.
Briviact 50 mg film-coated tablets Each 50 mg film-coated tablet contains 189 mg lactose. 
Briviact 50 mg filmom obložene tablete Jedna filmom obložena tableta od 50 mg sadrži 189 mg laktoze.
Open label extension studies 
Otvoreni nastavci ispitivanja
Briviact 75 mg film-coated tablets Each 75 mg film-coated tablet contains 283 mg lactose. 
Briviact 75 mg filmom obložene tablete Jedna filmom obložena tableta od 75 mg sadrži 283 mg laktoze.
A nasogastric tube or a gastrostomy tube may be used when administering brivaracetam oral solution. 
Za primjenu brivaracetam oralne otopine može se koristiti nazogastrična ili gastrostomska sonda.
Briviact oral solution is provided with a 5 ml and a 10 ml oral dosing syringe with their adaptor. 
Briviact oralna otopina izdaje se sa štrcaljkom za oralno doziranje od 5 ml i 10 ml i njihovim nastavkom.
Raspberry flavour (propylene glycol 90 % - 98 %) Purified water. 
karmelozanatrij sukraloza sorbitol, tekući glicerol (E422) aroma maline (propilenglikol 90% - 98%) pročišćena voda
Recommended starting dose 50 mg/day (or 100 mg/day)* 
50 mg/dan (ili 100 mg/dan)*
Briviact 100 mg film-coated tablets Each 100 mg film-coated tablet contains 377 mg lactose. 
Briviact 100 mg filmom obložene tablete Jedna filmom obložena tableta od 100 mg sadrži 377 mg laktoze.
You will use Briviact together with other medicines for epilepsy. 
Briviact ćete primjenjivati zajedno s drugim lijekovima za epilepsiju.
Common: may affect up to 1 in 10 people - flu - feeling very tired (fatigue) - convulsion, a feeling of ‘spinning' (vertigo) - feeling and being sick, constipation - pain or discomfort at the injection or infusion site - depression, anxiety, not being able to sleep (insomnia), irritability - infections of the nose and throat (such as the ‘common cold'), cough - decrease appetite 
Česte: mogu se javiti u do 1 na 10 osoba - gripa - izrazit umor - konvulzija, vrtoglavica (osjećaj da se sve oko Vas vrti) - mučnina, povraćanje, zatvor - bol ili nelagoda na mjestu primjene injekcije ili infuzije - depresija, tjeskoba, nesanica, razdražljivost
Brivaracetam is not recommended for use in monotherapy. 
Ne preporučuje se primjena brivaracetama u monoterapiji.